GSK

GSK_CY_2022_EFPIA_HCPO_Methodological_Note_ENGLISH

| Term | Definition |
|------------------|---|
| Corporate scope | GSK will issue one report for each country showing all Transfers of Value made to HCPs / |
| | HCOs in that country by GSK and by ViiV Healthcare. |
| Reporting date | GSK has defined two types of Transfers of Value for Reporting Date purposes: |
| | - a <i>Monetary Transfer of Value</i> is a payment of money made to an HCP/HCO by GSK |
| | either directly or through an intermediary (for example, fees for service). The Reporting |
| | Date for these Transfers of Value will be the actual payment date, irrespective of when |
| | the event happened (for example, when a consultancy fee is paid, not when the work took place). |
| | - a Non-monetary Transfer of Value is a benefit received from GSK either directly or |
| | through an intermediary <i>without</i> a monetary payment (a flight or a congress registration |
| | fee paid to a travel agent or events organiser, for example). The Reporting Date for these |
| | Transfers of Value will be the event date (for example, when the congress took place). |
| Value Added Tax | GSK has taken the decision to report values including VAT wherever possible due to the |
| | complexity of VAT regimes around Europe and the inconsistency of whether VAT may or |
| | may not be reimbursable depending on where the transaction took place and the country |
| | of residency of the HCPor HCO. All other taxes are included in the reported values |
| Currency | GSK records Transfers of Value in the currency in which the transaction took place. The |
| conversions | report will show all values in the currency of the country in which the report is made. |
| HCPs employed by | GSK will not report payments made to HCPs who are employed by GSK as staff members. |
| GSK | GSK considers that it would be inappropriate to the disclose an employee's salary, bonus, |
| | expenses and benefits. |
| Distributors | If a distributor is involved in the promotion of medicines on behalf of a Member |
| | Company in an EFPIA country, and is therefore under the operational control and |
| | guidance of that Member Company, then its activities are reportable by the Member |
| | Company in that country. |
| | In such cases GSK will provide the data as a standalone distributor report (using the |
| | structure set out in Schedule 2 of the EFPIA Code), based on the distributor's own |
| | methodology and policies. |
| Multi-year | Transfers of Value are reported on the relevant Reporting Date (payment date or event |
| contracts | date – see above) irrespective of the duration of the contract. |